Immunogenicity and Reactogenicity of Pneumococcal Polysaccharide and Conjugate Vaccines in Native Elders

Completed · Phase 1

Conditions studied: Pneumococcal Infections

In brief

To test the hypothesis that immune responses to 23-valent pneumococcal polysaccharide vaccine (PPV-23) could be improved in Alaska Native elders by immune priming with 7-valent pneumococcal conjugate vaccine (PCV-7), we assessed post-vaccination immune responses among Natives aged 55 years and older who were randomized into three arms: (1) one dose of PPV-23 according to current state and ACIP recommendations; (2) one dose of PCV-7 followed two months later with a dose of PPV-23; and (3) one dose of PCV-7 followed six months later with a dose of PPV-23.

Key facts

Study ID

NCT00153543

Run by

Centers for Disease Control and Prevention

People needed

86

Starts

2002-05-01

Expected to finish

2003-06-01

Last updated by the study team

2024-10-01

Who can join

Age: 55 and older, up to 70. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Age 55 to 70 years
• Alaska Native

You may not qualify if…

• Immune compromising condition
• Neurological disease
• Immune suppressive medication or immunoglobulin within 6 months
• Previous pneumococcal vaccination

Where it is running

• Alaska Native Medical Center — Anchorage, Alaska, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.